(Q38443324)

3 September 2017

title

Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer (English)

1 reference

estrogen-receptor positive breast cancer

3 September 2017

main subject

0 references

1 reference

Minoru Yoshida

10

0 references

Masakazu Toi

11

object named as

Masakazu Toi

1 reference

3 September 2017

1

Shigehira Saji

1 reference

3 September 2017

Masayo Kawakami

2

1 reference

3 September 2017

Shin-Ichi Hayashi

3

1 reference

3 September 2017

Nobuyuki Yoshida

4

1 reference

3 September 2017

Makiko Hirose

5

1 reference

3 September 2017

Shin-Ichiro Horiguchi

6

1 reference

3 September 2017

Akihiro Itoh

7

1 reference

3 September 2017

Nobuaki Funata

8

1 reference

3 September 2017

Stuart L Schreiber

9

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

3 September 2017

1 reference

3 September 2017

volume

24

1 reference

3 September 2017

issue

28

1 reference

3 September 2017

page(s)

4531-4539

1 reference

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Molecular markers for predicting response to tamoxifen in breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Progesterone receptors as a prognostic factor in Stage II breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Three proteins define a class of human histone deacetylases related to yeast Hda1p

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

HDAC6 is a microtubule-associated deacetylase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Development of cDNA microarray for expression profiling of estrogen-responsive genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Cell biology: Tubulin acetylation and cell motility

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1208646

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1208646

1 reference

Dimensions Publication ID

3 September 2017

1047808841

0 references

1 reference